Impact of COVID-19 on new pharmacotherapy for insomnia: A matched cohort study using the national insurance claims database in Japan
COVID-19 significantly associates with an elevated risk of insomnia medication initiation, emphasizing the necessity for mental health support in post-COVID-19 care. This study offers insights into the pandemic's influence on pharmacological treatment practices.
Authors
- Masanori Ito
- Daisuke Miyamori (ORCID: https://orcid.org/0000-0002-1352-3738)
- Shuhei Yoshida (ORCID: https://orcid.org/0000-0002-6747-1857)
- Wataru Omori
- Saori Kashima
Institutions
- Hiroshima University (JP)
- Planetary Systems (United States) (US)
- Hiroshima University Hospital (JP)
- Kure Medical Center (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1371/journal.pone.0341416
- Primary Topic
- Sleep and related disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science